Compare the findings at Peptide Pros USA
The useful comparison starts with the job each experiment asked its peptide to do.
Measured outcomes
| Compound | Experimental task | Finding to carry forward |
|---|---|---|
| Sermorelin | Linear growth in prepubertal children with GH deficiency | First-year height velocity increased; adult wellness requires its own outcomes. |
| Ipamorelin | Tolerating a meal after bowel resection | The randomized trial missed its primary endpoint (P=0.15). |
| CJC-1295 DAC | Sustaining GH and IGF-1 in healthy adults | Hormone elevation lasted days; broader practical benefits were not established. |
| CJC-1295 / ipamorelin | Proposed cooperation between receptor pathways | Receptor co-activation increased cAMP in engineered cells; a controlled human blend trial is absent. |
I decline an overall ranking of these mismatched tasks. The pediatric growth finding is clinically concrete. The CJC-1295 pharmacology is technically impressive. Ipamorelin’s surgical result is disappointing. Each judgment has a different object.
Duration and formulation
In the sermorelin study in healthy men, the GH response lasted about 3 hours despite rapid peptide clearance. Ipamorelin modeling in healthy male volunteers found an approximately 2-hour terminal half-life and a GH peak about 40 minutes after administration. Those are different measures, so I resist putting them into a single fastest-to-slowest ranking.
For CJC-1295 DAC in healthy adults, the estimated peptide half-life was 5.8–8.1 days, with GH increased for 6 days or more and IGF-1 for 9–11 days. No-DAC Modified GRF 1-29 lacks the albumin-binding feature responsible for that persistence. The DAC findings cannot be transferred wholesale to no-DAC.
FDA history and compounding
| Compound | United States status described here |
|---|---|
| Sermorelin | Prior pediatric FDA approval, NDA 020443; approved product withdrawn for commercial reasons. Compounded sermorelin has no FDA approval. |
| Ipamorelin | Never FDA-approved. Ipamorelin acetate remains Category 2 under 503B and also has a withdrawn 503A nomination, with safety concerns intact. |
| CJC-1295 | Never FDA-approved. A withdrawn bulk-substance nomination remains accompanied by immunogenicity concerns. |
| CJC-1295 / ipamorelin | Neither component is FDA-approved; the fixed blend has no controlled human trial. |
The ipamorelin category description follows FDA’s page current as of April 22, 2026. A withdrawn nomination confers no permission to compound and supplies no move into Category 1. Clinical suitability and lawful compounding require their own assessment. All four entries are WADA S2-prohibited.
Safety across the group
The secretagogue safety review describes generally favourable short-term tolerability across the class, while emphasizing glucose and insulin-sensitivity concerns and the need for long-term cancer and mortality data. It is a synthesis across compounds, rather than a safety trial of every item in this table.
Accumulated exposure is my largest reservation: the very property presented as a pro can prolong an unwanted effect as well. The existing studies leave sustained GH/IGF-1 stimulation, fluid retention and theoretical tumour-promotion concerns incompletely resolved. Research-grade material also lacks pharmaceutical quality assurance. These limitations prevent a reliable safety ranking.